Preliminary observations J. Endocrinol. 85, 42P-43P] had suggested that the major hypothalamic somatoliberin (growth-hormone-releasing factor) was a larger peptide than the other characterized hypothalamic factors, with an elution position on Sephadex G-50 between those of neurophysin and corticotropin. The present paper reports the isolation and preliminary characterization of pig hypothalamic somatoliberin. Acid extracts of pig stalk median eminence were purified by gel filtration and preparative and analytical high-pressure liquid chromatography to yield a preparation that was specific in the release of somatotropin (growth hormone) in vitro, giving a steep dose-response curve at doses in the range 0.20-3.Ong. Amino acid analysis revealed a non-cysteine-containing peptide with a high number of glutamate (or glutamine) and aspartate (or asparagine) residues. The peptide had about 56-57 amino acid residues and an apparent molecular weight of 6400, in keeping with its elution position on a column of Sephadex G-50.
purification and characterization of hypothalamic somatoliberin (growth-hormone-releasing factor) from bovine, sheep and pig tissue (Dhariwal et al., 1965; Schally et al., 1969; Wilber et al., 1971; Malacara et al., 1972; Stachura et al., 1972; Wilson et al., 1974; Johansson et al., 1974; Boyd et al., 1978; Nair et al., 1978) . In all of these reports the active factor involved is of low molecular weight, less than 2000 (by gel filtration), in keeping with the size of the other identified hypothalamic releasing factors. The material isolated by Nair et al. (1978) from 6000 bovine hypothalami was active in vivo at doses of lOOng, when injected into the systemic circulation, and of lOng when injected into the portal vessels. Enzymic studies revealed the lowmolecular-weight peptide to have a pyroglutamate N-terminal residue, and a free C-terminal. The other characterized releasing factors thyroliberin (thyrotropin-releasing factor) and luliberin (luteinizinghormone-releasing factor) also have pyroglutamate residues at their N-terminals. However, in contrast, somatoliberins of much larger molecular weight have been detected in extracts of tumour tissue (Beck et al., 1973; Frohman et al., 1980) . The peptide partially purified and characterized by the latter team, from non-pituitary tumours of patients with Abbreviation used: h.p.l.c., high-pressure liquid chromatography. Vol. 209 acromegaly, was active, in vitro, at doses of 40ng of protein/ml. By gel filtration this active material had an apparent molecular weight of 8000, although a further minor peak of activity having a molecular weight in the range 15 000-30000 was also detected.
This peptide was found to have blocked N-and C-terminals.
We have previously presented chromatographic data to suggest that rat and pig hypothalamic somatoliberins have molecular weights of approx. 6000 , with an elution position on Sephadex G-50 between those of neurophysin and corticotropin. In the present paper we describe the purification and characterization of this somatoliberin from extracts of pig stalk median eminence.
Materials and methods Materials
Two hundred pig stalk median eminences were obtained fresh from the Dunmow Flitch Bacon Co. Abattoir, Great Dunmow, Suffolk, U.K., within 20-40min (Basle, Switzerland) , and the antibiotics benzylpenicillin and streptomycin were purchased as a combined preparation, crystamycin, from Glaxo Laboratories (Greenford, Middx., U.K.).
The reagents for the radioimmunoassay of rat somatotropin (growth hormone) and rat lutropin (luteinizing hormone) were kindly supplied by the National Pituitary Hormone Agency (Bethesda, MD, U.S.A.). The reference preparation of rat somatotropin used was rat GH-RP-4, and the antiserum was rat GH-S-4; rat somatotropin for radio-iodination was purified in our laboratory, and was fully cross-reactive with the antiserum supplied. The reference preparation of rat lutropin was rat LH-RP-1, and the antiserum was rat LH-S-3; as material for radio-iodination, rat LH-I-3 was used. Synthetic 18-argininelvasopressin was purchased from Ferring (Malm6, Sweden), and synthetic [8-lysinelvasopressin, synthetic somatostatin and oxytocin were all purchased from Penninsula Laboratories (San Carlos, CA, U.S.A.). Native human corticotropin was purified in this laboratory (Scott & Lowry, 1974 Bartholomew's Hospital, London, U.K.). All peptides and proteins were iodinated by using the iodogen technique (Salacinski et al., 198 1) .
Extraction and gelfiltration
The fragments of pig stalk median eminence (6.6 g) were extracted by homogenization in 60 ml of ice-cold 0.01 M-HCI in a Silverson homogenizer, and the high-molecular-weight proteins were precipitated by the addition of NaCl (5 mg/ml). After centrifugation the pellet was re-extracted with a further 20ml of 0.01 M-HCI, NaCl (5 mg/ml) was added and the mixture was centrifuged. The combined supernatants were filtered through pre-washed glass-wool to remove lipid-like particulate matter, and the filtered extract was immediately loaded on to a Sephadex G-15 column (5 cm internal diam. x 29 cm length) connected in series to a Sephadex G-50 column (5 cm x 83 cm). The columns were equilibrated with and developed with 0.01 M-HCl/0.9% NaCl/0.1% ascorbic acid at a flow rate of 13.8 ml/h; 40min fractions were collected at 4°C; samples were taken from every third fraction and diluted directly in the perfusion buffer.
Rat hypothalamic extract
The hypothalamic pituitary stalks (1-2mg wet wt.) from freshly killed female Wistar rats were extracted in 0.01 M-HCI at a concentration of one fragment/ml. After the addition of NaCl (9 mg/ml) the extract was centrifuged at 100OOg for 30min. The supernatant was neutralized for the bioassay by the addition of 10ul of 1.1 M-NaHCO3/ml, or frozen at acid pH until required. H.p.l.c.
The somatoliberin regions obtained after gel filtration of the extract of pig stalk median eminences were pooled, made 1% (v/v) with respect to trifluoroacetic acid and pumped directly on to the preparative h.p.l.c. columns. All h.p.l.c. was performed at room temperature, and the elution of peptides was monitored by recording the absorbance at 280nm. Further details of individual h.p.l.c. runs are given in the legends to Figs. 2-5. Amino acid analysis Samples were hydrolysed in 6 M-HCl (with a crystal of phenol) for 24h in vacuo at 1150C. Analysis was performed with a JEOL JLC-6AH automatic amino acid analyser. For micro amino acid analysis the o-phthaldialdehyde fluorescence detection system of Roth (1971) was used. Cysteine residues were detected as cysteic acid after oxidation of cysteine residues with performic acid before hydrolysis.
Radioimmunoassays
Rat somatotropin was measured by using a modification of the method suggested by the N. (Gillies & Lowry, 1978) . The methodology for the oxytocin immunoassay was identical with that of the vasopressin immunoassay, and that for neurophysin was identical with the somatotropin immunoassay. The corticotropin radioimmunoassay method was that of Rees et al. (1971) , and the somatostatin immunoassay method followed that of Penman et al. (1979) .
Somatoliberin bioassay
The perfused isolated rat anterior-pituitary-cell column of Gillies & Lowry (1978) was adapted as a bioassay for somatoliberin as described previously Lowry et al., 1980) . Briefly, the anterior-pituitary cells from female Wistar rats (200-250 g) were dispersed by trypsinization NP ACTH (0.25%) and mechanical agitation, and mixed with 0.5g Bio-Gel P2 pre-swollen in 0.9% NaCI, and washed with perfusion medium containing antibiotics (25,ug of streptomycin/ml and 15,pg of benzylpenicillin/ml) and ascorbic acid (30,ug/ml). The suspension of cells and Bio-Gel was packed into a small plastic column and perfused with perfusion medium containing human serum albumin (0.25%) and Trasylol (100 kallikrein-inhibitory units/ml) in addition to the antibiotics and ascorbic acid, at a flow rate of 30ml/h. After a 1.5 h equilibration period the cell column was stimulated with test material for 2 min every 10 min; 2 min fractions were collected and assayed for rat somatotropin by radioimmunoassay.
Treatment ofdata Rat somatotropin was expressed in terms of the N.I.A.M.D.D. reference preparation, and was the total amount of somatotropin released above background. To establish a logarithmic relationship with the dose, samples were applied randomly in quadruplicate and the results were analysed by using Student's t test and regression analysis.
Results

Gelfiltration
Samples were tested for somatoliberin activity by bioassay at a dilution of 1:200. As shown in Fig. 1 (Zingg & Patel, 1979) , 12000, 4000 and 2000 (Conlon et al., 1978; Noe et al., 1978; Schally et al., 1980; Spiess & Vale, 1980 (Fig. 3 ), which were eluted at 59% and respectively) and which were well separated from the other u.v.-absorbing material. These peaks did not cross-react in either the vasopressin or the oxytocin radioimmunoassays. Samples from the peak tubes (fractions 12 and 28) were taken for amino acid analysis, with the use of both ninhydrin and o-phthaldialdehyde fluorescence detection of amino acids. As shown in Table 1 , the two peptides were not of similar composition and did not correspond to any previously described peptide.
The somatoliberin-bioactive material (tested at a dilution of 1:200) was eluted as a broad peak in 90-92% solvent B (retention time 21.8-22.2min) between two incompletely separated peaks of immunoreactive neurophysin. Neither the somatoliberin bioactivity nor the neurophysin immunoreactivity was eluted as a well-defined u.v.-absorbing peak, but occurred in a broad region of u.v. absorbance. Peak tubes of immunoreactive neurophysin contained 25.2,ug and 35.2,ug of neurophysin respectively. After gel filtration the peak tube of immunoreactive neurophysin contained 93.6,ug of neurophysin, indicating a loss of 39% of immunoreactive neurophysin during preparative h.p.l.c.
The main somatoliberin-containing fractions (109-111 in Fig. 3 ) were further purified by h.p.l.c. on a cyanopropylsilica column. Samples were tested for somatoliberin activity (at a 1:200 dilution) and for immunoreactive neurophysin. There was a near-complete separation of somatoliberin bioactivity from neurophysin immunoreactivity (Fig. 4) . Somatoliberin was eluted in 75% solvent B (retention time 7.2min), whereas immunoreactive neurophysin was associated with the smaller, later-eluted, peak occurring at 85% solvent B (retention time 9.0 min). By radioimmunoassay, the recovery of immunoreactive neurophysin was 99%.
Vol. 209 dilution of 1:500) was associated with the main u.v.-absorbing peak (retention time 9.2 min; elution in 87% solvent B). Immunoreactive neurophysin was eluted before the somatoliberin-active peak, with a retention time of 8.0min.
Samples from fractions 46 and 47 (Fig. 5) were taken for amino acid analysis, with the use of both ninhydrin and o-phthaldialdehyde fluorescence detection of amino acid residues. Fraction 47 was oxidized with performic acid to permit the detection of cysteine (as cysteic acid). The results are shown in Table 1 . The somatoliberin material was characterized by a high number of glutamate (or glutamine) residues, with aspartate (or asparagine) being the next predominant residue. Cysteic acid was not detected in the hydrolysate of fraction 47. Amino sugars were also not detected. Tryptophan residues were estimated as 0-1/molecule, calculated from the absorbance at 280 nm. There was only 1 tyrosine residue/molecule. Thus the pig somatoliberin molecule has about 56-57 residues, which would give a molecular weight of approx. 6400, consistent with its elution position on Sephadex G-50 between immunoreactive neurophysin and corticotropin.
The material from fraction 46 and 47 (Fig. 5 ) was very active in releasing somatotropin from the anterior-pituitary-cell column over the dilution range 1:8000-1:500 (approx. 0.1-lOng of peptide), and gave a steep dose-response curve (P = <0.005) (Fig. 6) . When matched for the dose/dilution required to give a release of 450ng of rat somatotropin/ml, the regression coefficient, B, for pig somatoliberin was 3378 and for an extract of rat stalk median eminence was 2323. Neither corticotropin nor rat lutropin was released from the anterior-pituitary-cell bioassay after stimulation with this large-molecular-weight pig stalk-median-eminence somatoliberin. 
Discussion
Pig hypothalamic somatoliberin activity was purified from an acid extract of pig stalk median eminence by gel filtration and preparative and analytical h.p.l.c. The final purification step, yielding less than 16,g of active material, resulted in a near-complete separation of somatoliberin from its main contaminant (neurophysin). Final amino acid analysis both before and after performic acid oxidation, with the use of both ninhydrin and o-phthaldialdehyde fluorescence detection, revealed a large peptide with a high number of glutamate (or glutamine) and aspartate (or asparagine) residues (accounting for 28% of the total residues), no cysteine and low amounts of methionine, threonine, tyrosine, phenylalanine and histidine. Basic amino acid residues (arginine and lysine) accounted for 12% of the total peptide. Tryptophan was estimated
Vol. 209 at 0-1 residues/molecule. The lack of cysteine in the final amino acid analysis indicated that the somatoliberin fraction analysed was free from neurophysin.
With about 56-57 amino acids, the peptide molecule would have a molecular weight of approx. 6400, in agreement with the suggested molecular weight of the tumour somatoliberin reported by Frohman et al. (1980) . Our peptide also appears to have a great similarity to that found by Schally et al. (1969) in that both have a high glutamate content. However, our material is distinguished by a larger molecular weight and the presence of additional amino acids (namely arginine, proline, threonine, glycine, methionine, phenylalanine, isoleucine and aspartate). The lack of cysteine in our material is in agreement with the observation by Arimura et al. (1967) that thioglycollate failed to inactivate hypothalamic somatoliberin. Fig. 5 ) and a crude extract of rat stalk median eminence (U) were prepared as described in the Materials and methods section. At dose/dilution 1 both secretagogues released approx. 450ng of rat somatotropin/ml.
The difficulty in freeing hypothalamic somatoliberin from immunoreactive neurophysin, together with our earlier observation that both oxytocin and vasopressin, both bound by the neurophysins, stimulated the release of rat somatotropin from the anterior-pituitary-cell column ; J. E. C. Sykes & P. J. Lowry, unpublished work), raised the possibility that the peptide isolated was part of a complex, analogous to the proposed corticoliberin-releasing factor complex (consisting of [8-argininelvasopressin acting synergistically with the other factors; Gillies . Furthermore, the somatoliberin-and oxytocin-stimulated release of rat somatotropin was inhibited by synthetic somatostatin in a dose-dependent manner, and with parallel dose-inhibition curves (J. E. C. Sykes & P. J. Lowry, unpublished work). However, the large-molecular-weight pig somatoliberin released only somatotropin, and thus must be considered as the major physiological somatoliberin, whereas both oxytocin and vasopressin are capable of releasing other adenohypophysial hormones (Gillies & Lowry, 1978 ; J. E. C. Sykes & P. J. Lowry, unpublished work) .
A somatoliberin with a molecular weight greater than that of the previously identified hypothalamic factors is implied by the properties of the somatoliberin receptor proposed by Momany et al. (1981) . Furthermore, Guillemin (1980) described the isolation from hypophysial and neurohypophysial extracts of a somatotropin-releasing peptide that had 35-37 amino acid residues/molecule, including 2 cysteine residues. More recently, Bohlen et al. (1982) have reported the isolation of a tumour somatoliberin with an estimated molecular weight of about 5000.
It is difficult to equate the undoubted somatotropin-releasing activity of the small peptide isolated by Nair et al. (1978) with the specific release of rat somatotropin in vitro caused by our much larger peptide. In view of the stimulatory effect in vivo of the former group's peptide on somatotropin synthesis and release, it is difficult to envisage their material as being an artifact. Like Frohman et aL (1980) , we must conclude (a) that the two peptides are unrelated or (b) that our material represents a precursor somatoliberin, 'big-somatoliberin', with full or enhanced bioactivity. In view of the reported greater bioactivity of somatostatin-28 compared with somatostatin-14 in inhibiting somatotropin release (Spiess & Vale, 1980) , there always remains the possibility that the smaller hypothalamic peptides isolated so far are only bioactive fragments of a larger molecule. This could also be implied from the observation by Vale et al. (1981) that only the C-terminal region of the 41-residue sheep corticoliberin (corticotropin-releasing factor) was required for full activity, allowing the possibility that smaller corticoliberin-like peptides could exist that are N-terminally shortened but that still retain the bioactive C-terminal. Interestingly, trypsin treatment of a partially purified preparation of pig somatoliberin only partially abolished its somatotropin-releasing properties (J. E. C. Sykes & P. J. Lowry, unpublished work). Thus the large-molecularweight somatoliberin described in the present paper could represent the precursor of the smaller peptides described by others.
